RT Journal Article
SR Electronic
T1 Elevated circulating CD16+ monocytes and TLR4+ monocytes in older adults with multiple cardiometabolic disease risk factors: A cross-sectional analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21255420
DO 10.1101/2021.04.13.21255420
A1 Melissa M. Markofski
A1 Michael G. Flynn
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.13.21255420.abstract
AB We endeavored to examine relationships between circulating monocyte phenotype and cardio-metabolic disease risk, in healthy, older adults. We performed a secondary data analysis on men and women, 55-75 yr, who were assigned to groups based on cardio-metabolic risk factors other than age. Subject in the low risk group (n=16, 12 females) had fewer than three risk factors. Subjects in the elevated risk group (n=29, 19 females) had three or more risk factors. Along with baseline screening for fitness and body composition, resting blood samples were assessed for markers of inflammation including: monocyte phenotype (inflammatory monocytes), monocyte cell-surface TLR4 expression, and serum C-reactive protein. The low risk group had a smaller (19.3% difference; p<0.0001) waist circumference and lower body fat weight (36.3%; p<0.0001), but higher max (45.5%; p=0.0019). There were no mean differences (p>0.05) between the low and elevated risk groups for BMI, serum cholesterol, fasting glucose, or leg press 1RM. The low risk group had lower CRP (114.7%, p=0.0002), higher CD14+CD16- (classical) monocytes (6.7%; p=0.0231) and fewer CD14+CD16+ (inflammatory) monocytes (46.2%; p=0.0243) than the elevated risk group. The low risk group also had a lower percentage of CD14+CD16+ monocytes that were positive for TLR4 (14.0%; p=0.0328). Older men and women with fewer cardio-metabolic risk factors had lower serum and cellular markers of inflammation and higher aerobic capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMMM: Support for this work was provided by the National Cancer Institute of the National Institutes of Health via P20CA221697 to the University of Houston and P20CA221696 and P20CA221696-02S1 to the University of Texas, MD Anderson Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the institutional review board at Purdue University (protocol reference number 0801006394)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request to corresponding author